HALO

As of 2026-10-26, HALO scores 70out of 100 on QNTM’s five-factor quantitative model, a high conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. HALO trades at $128.01, 16% below the band floor.

HALO scores 70 out of 100 on QNTM's five-factor model — a high-conviction reading — 70 puts it among the strongest factor profiles the model tracks. Its strongest factor is momentum at 90 (exceptional), where price trend and relative strength are working in its favor, followed by quality at 80. The weakest is sentiment at 11, where sentiment signals are working against it. Among Healthcare stocks it ranks in roughly the top 1% of the Healthcare names the model scores.

On valuation, HALO is priced near the floor of its own recent range — the cheap end on the model's valuation read. The profile is lopsided — a few factors carry it while others drag, so the composite masks real disagreement underneath. The blended composite before the macro overlay was 71. Same-sector names the model rates nearby include VEEV, THC, CON.

This is a descriptive factor read on HALO, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where HALO sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for HALO runs $152.69–$231.34. Current price $128.01 sits 16% below the band floor. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.